Antiobesity Medication Use in 2.2 Million Adults Across Eight Large Health Care Organizations: 2009‐2015

Saxon, David; Iwamoto, Sean J.; Mettenbrink, Christie; McCormick, Emily; Arterburn, David; Daley, Matthew F.; Oshiro, Caryn; Koebnick, Corinna; Horberg, Michael A.; Young, Deborah Rohm; Bessesen, Daniel H.

doi:10.1002/oby.22581

Cited by 101 publications

(118 citation statements)

References 26 publications

Supporting

Mentioning

111

Contrasting

Unclassified

Order By: Relevance

“…It may also not be generalizable to other populations and as a result may not accurately assess the burden of COVID‐19 on obesity‐related health and behaviours in lower socioeconomic status and/or ethnic minority populations who are disproportionately more affected by obesity and COVID‐19 4 . Participants were established weight management patients with secured health insurance, which is not representative of the average American challenged with obesity in which <2% receive anti‐obesity medications 33 and <1% undergo MBS 34 . In addition, the sample size of ethnic minority groups is relatively small in this study, although we used robust statistical methods to ensure the accuracy of our results, the type II error may increase due to possibly insufficient power.…”

Section: Discussionmentioning

confidence: 99%

Impact of COVID‐19 stay‐at‐home orders on weight‐related behaviours among patients with obesity

et al. 2020

View full text Add to dashboard Cite

Summary How the impact of the COVID‐19 stay‐at‐home orders is influencing physical, mental and financial health among vulnerable populations, including those with obesity is unknown. The aim of the current study was to explore the health implications of COVID‐19 among a sample of adults with obesity. A retrospective medical chart review identified patients with obesity from an obesity medicine clinic and a bariatric surgery (MBS) practice. Patients completed an online survey from April 15, 2020 to May 31, 2020 to assess COVID‐19 status and health behaviours during stay‐at‐home orders. Logistic regression models examined the impact of these orders on anxiety and depression by ethnic group. A total of 123 patients (87% female, mean age 51.2 years [SD 13.0]), mean BMI 40.2 [SD 6.7], 49.2% non‐Hispanic white (NHW), 28.7% non‐Hispanic black, 16.4% Hispanic, 7% other ethnicity and 33.1% completed MBS were included. Two patients tested positive for severe acute respiratory syndrome coronavirus 2 and 14.6% reported symptoms. Then, 72.8% reported increased anxiety and 83.6% increased depression since stay‐at‐home orders were initiated. Also 69.6% reported more difficultly in achieving weight loss goals, less exercise time (47.9%) and intensity (55.8%), increased stockpiling of food (49.6%) and stress eating (61.2%). Hispanics were less likely to report anxiety vs NHWs (adjusted odds ratios 0.16; 95% CI, 0.05‐0.49; P = .009). Results here showed the COVID‐19 pandemic is having a significant impact on patients with obesity regardless of infection status. These results can inform clinicians and healthcare professionals about effective strategies to minimize COVID‐19 negative outcomes for this vulnerable population now and in post‐COVID‐19 recovery efforts.

show abstract

Section: Discussionmentioning

confidence: 99%

Impact of COVID‐19 stay‐at‐home orders on weight‐related behaviours among patients with obesity

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Management of obesity requires multidisciplinary approaches including diet, food supplement, exercise, behavior change, drug, medical device, gut microbiome manipulation, and surgery [1,[4][5][6][7][8][9]. The annual obesity treatment market is around $6 billion.…”

Section: Introductionmentioning

confidence: 99%

Gut Microbiome in Obesity Management

Heshmati¹

2020

Weight Management

View full text Add to dashboard Cite

Obesity is a worldwide pandemic causing increased morbidity/mortality and high cost for the society. Management of obesity requires multidisciplinary approaches including diet, food supplement, exercise, behavior change, drug, medical device, gut microbiome manipulation, and surgery. Over the past two decades, there has been a growing awareness of the importance of gut microbiome in human health and disease. Profound changes affecting the diversity and the abundance of gut microbiome are associated with several disorders including obesity. A decrease in microbiome diversity and an increase in the ratio of Firmicutesto-Bacteroidetes phyla have been reported in obese subjects. The gut microbiome can be manipulated to change the host metabolism and manage obesity. Potential interventions include diet (e.g., low calories, low fat, and high fiber), prebiotics (e.g., inulin, lactulose, and resistant starch), probiotics (e.g., yogurt, cheese, and milk), synbiotics (combination of prebiotics and probiotics), bariatric surgery (e.g., Roux-en-Y gastric bypass), and fecal microbiota transplantation (through colonoscopy, esophagogastroduodenoscopy, orogastric tube, or oral capsule). A better understanding of the interactions between different diets and gut microbiome should help the development of new guidelines for the prevention and management of obesity.

show abstract

Section: Introductionmentioning

confidence: 99%

Anti-Obesity Medical Devices

Heshmati¹

2020

Weight Management

View full text Add to dashboard Cite

Obesity is a major health problem worldwide responsible for increased morbidity/mortality and high cost for the society. Management of obesity requires multidisciplinary approaches including diet, food supplement, exercise, behavior change, drug, medical device, gut microbiome manipulation, and surgery. Antiobesity medical devices are an option for subjects who have not responded to more conservative medical treatments but want an alternative to surgery. Compared to bariatric surgery, they have the advantage of being less invasive, easier to perform, and reversible. In the United States of America (USA), based on the expected weight loss, the Center for Devices and Radiological Health (CDRH) of the Food and Drug Administration (FDA) categorizes anti-obesity medical devices as weightloss devices or weight-management devices. The weight-loss devices include gastric band devices, gastric space-occupying devices, and gastric emptying devices. The weight-management devices include oral removable palatal space-occupying devices and ingested transient gastric space-occupying devices. The effectiveness, safety, and cost of anti-obesity medical devices vary considerably by the type of medical device. Their use should always be combined with lifestyle changes. Considering the large market size of obesity treatment, anti-obesity medical devices can play a major role in the management of obesity.

show abstract

Antiobesity Medication Use in 2.2 Million Adults Across Eight Large Health Care Organizations: 2009‐2015

Cited by 101 publications

References 26 publications

Impact of COVID‐19 stay‐at‐home orders on weight‐related behaviours among patients with obesity

Impact of COVID‐19 stay‐at‐home orders on weight‐related behaviours among patients with obesity

Gut Microbiome in Obesity Management

Anti-Obesity Medical Devices

Contact Info

Product

Resources

About